Siscocorp Logo (CNW Group/Predictiv AI Inc.)
TORONTO, Feb. 19, 2021 /PRNewswire/ -
Predictiv AI Inc. (TSX-V: PAI) (OTC: INOTF) (FSE: 71TA) (
Predictiv AI or the
Company ), www.predictiv.ai, a software and solutions provider in the artificial intelligence markets is pleased to announce that
Security Identification Systems Corp. (SISCO), www.siscocorp.com, has joined ThermalPass as a channel reseller and distributor to market and sell the ThermalPass to its U.S. customers in hospitality, healthcare, commercial enterprises and government. ThermalPass will be paired with the SISCO Fast-Pass® Visitor Management System to assist with track-and-trace efforts and to provide enhanced peace of mind to building occupants and visitors.
Share this article
Share this article
BIRMINGHAM, Ala., Feb. 19, 2021 /PRNewswire/ Encompass Health Corp. (NYSE: EHC) today announced it has been named to Fortune World s Most Admired Companies for 2021. Encompass Health, a leader in integrated healthcare services and the largest owner and operator of inpatient rehabilitation hospitals in the United States, was listed in the Health Care: Medical Facilities category. We are extremely honored to be named one of this year s World s Most Admired Companies by Fortune. This is a true reflection of the preeminent care our employees provide to more than 400,000 patients annually through our rehabilitation hospitals and home care services, said Mark Tarr, president and chief executive officer of Encompass Health. We are grateful to all who put their trust in our Company and will continue to make a meaningful difference in the communities we serve throughout the country.
Children s Mercy Kansas City s New Research Building Opens, Accelerating the Discovery of Cures and Transforming Pediatric Care
News provided by
Share this article
Share this article
KANSAS CITY, Mo., Feb. 19, 2021 /PRNewswire/ Children s Mercy Kansas City announced the opening of its new 9-story, 375,000 square-foot, pediatric research facility located on the hospital s Adele Hall campus in the heart of downtown Kansas City. The new building is home to the Children s Mercy Research Institute® (CMRI), which was established in 2015 to accelerate precise diagnoses and treatments for complex childhood diseases and move kids to the forefront of research discoveries.
Genomic variances based on children treated at Children’s Mercy are displayed on the all-glass façade of the new Children’s Mercy Research Institute building and illuminated at night.
AbbVie to Present at the Cowen 41st Annual Health Care Conference
News provided by
Share this article
Share this article
NORTH CHICAGO, Ill., Feb. 19, 2021 /PRNewswire/ AbbVie (NYSE: ABBV) will participate in the Cowen 41
st Annual Health Care Conference on Wednesday, March 3, 2021. Michael Severino, M.D., vice chairman and president, Robert A. Michael, executive vice president and chief financial officer, and Jeffrey R. Stewart, executive vice president, commercial operations, will present virtually at 10:40 a.m. Central time.
A live audio webcast of the presentation will be accessible through AbbVie s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
Appeals Court Upholds False Advertising Verdict Against Sellers of VSL#3® Probiotic
News provided by
Share this article
Share this article
ROCKVILLE, Md., Feb. 19, 2021 /PRNewswire/ ExeGi Pharma LLC ( ExeGi ), a company focused on developing live biotherapeutic ( LBP ) drugs and probiotics, announced today that the United State Court of Appeals for the Fourth Circuit has upheld a prior $15 million jury verdict in which the sellers of the VSL#3
® probiotic were found liable for false advertising.
United States Court of Appeals for the Fourth Circuit
Appeals Court Upholds False Advertising Verdict Against Sellers of VSL#3 Probiotic
Today s judgment affirms the findings from a 2018 trial in the U.S. District Court for the District of Maryland, which was brought by ExeGi and Professor Claudio De Simone, an inventor of probiotic products. The original case sought to declare that Professor De Simone owned the rights to a proprietary probiotic formulation (known as the De Sim